These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2862769)

  • 1. Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
    Hippius H; Ackenheil M; Müller-Spahn F
    Adv Biochem Psychopharmacol; 1985; 40():9-13. PubMed ID: 2862769
    [No Abstract]   [Full Text] [Related]  

  • 2. beta-Endorphin, cortisol, and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathology.
    Naber D; Albus M; Muller F; Burke H; Welter D; Ackenheil M; Hippius H
    Psychopharmacol Bull; 1982 Oct; 18(4):224-6. PubMed ID: 6130563
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance?
    Naber D; Fischer H; Ackenheil M
    Commun Psychopharmacol; 1979; 3(1):59-65. PubMed ID: 38032
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term effects of neuroleptic drugs on the neuroendocrine system.
    Meltzer HY
    Adv Biochem Psychopharmacol; 1985; 40():59-68. PubMed ID: 2862768
    [No Abstract]   [Full Text] [Related]  

  • 5. Basal and stimulated levels of prolactin, TSH, and LH in serum of chronic schizophrenic patients long-term treated with neuroleptics: relations to psychopathology.
    Naber D; Ackenheil M; Laakmann G
    Adv Biochem Psychopharmacol; 1980; 24():419-23. PubMed ID: 6105792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathology.
    Naber D; Albus M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Wissmann J; Ackenheil M
    Psychiatry Res; 1985 Nov; 16(3):207-19. PubMed ID: 2868473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diurnal rhythms of plasma cortisol, beta-endorphin and prolactin, and cerebrospinal fluid amine metabolite levels before suicide. Case report.
    Dent RR; Ghadirian AM; Kusalic M; Young SN
    Neuropsychobiology; 1986; 16(2-3):64-7. PubMed ID: 2438587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical assessment of dopamine receptor blockade.
    Sedvall G; Bjerkenstedt L; Lindström L; Wode-Helgodt B
    Life Sci; 1978 Aug; 23(5):425-9. PubMed ID: 29184
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of yohimbine on release of anterior pituitary hormones.
    Goldberg MR; Jackson RV; Krakau J; Island DP; Robertson D
    Life Sci; 1986 Aug; 39(5):395-8. PubMed ID: 3016439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
    Chen YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683
    [No Abstract]   [Full Text] [Related]  

  • 11. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The two-syndrome concept and neuroendocrinology of schizophrenia.
    Crow TJ; Ferrier IN; Johnstone EC
    Psychiatr Clin North Am; 1986 Mar; 9(1):99-113. PubMed ID: 2870481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of cigarette smoking on endocrine function in man].
    Yao M; Narita M; Baba S; Kudo M; Kudo T; Oyama T
    Masui; 1985 Aug; 34(8):1105-14. PubMed ID: 2999461
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
    Tripodianakis J; Markianos M; Garelis E
    Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroendocrinology and schizophrenia research].
    Müller-Spahn F
    Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopaminergic mediation of beta-endorphin-induced prolactin secretion.
    Van Loon GR; De Souza EB; Shin SH
    Neuroendocrinology; 1980 Oct; 31(4):293-6. PubMed ID: 6252497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia.
    Verhoeven WM; van Ree JM; Westenberg HG; Krul JM; Brouwer GJ; Thijssen JH; de Wied D; van Praag HM; Ceulemans DL; Kahn RS
    Psychiatry Res; 1984 Apr; 11(4):329-46. PubMed ID: 6204351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.